Henry Schein, Inc.
62.32-0.89 (-1.41%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · HSIC · USD
Key Stats
Market Cap
7.56BP/E (TTM)
20.04Basic EPS (TTM)
3.11Dividend Yield
0%Recent Filings
8-K
Breslawski exits senior role
Henry Schein announced on September 5, 2025, that James Breslawski fully departed his senior advisor role on the Executive Management Committee, following his earlier transition from president on April 1, 2025. He will receive severance payments and benefits under the company's Executive Severance Plan. This completes the leadership shift. The filing discloses no further operational impacts.
10-Q
Q2 FY2025 filing overview
Henry Schein filed its Q2 10-Q for the quarter ended June 28, 2025, but the document provided contains only the cover page and an exhibit detailing amendments to its Supplemental Executive Retirement Plan effective September 1, 2025, with no financial statements or results disclosed. The plan update adjusts vesting schedules, contribution rules, and payment options for select executives, including lump-sum distributions post-termination and deferral elections compliant with Section 409A. No revenue, earnings, or balance sheet figures appear, so year-over-year or quarter-over-quarter changes cannot be assessed. Liquidity and debt details are absent. Executives face risks from plan changes tied to employment termination.
8-K
Q2 sales up, EPS down
Henry Schein reported Q2 2025 net sales of $3.2 billion, up 3.3% year-over-year, driven by 6.1% medical distribution growth and 7.4% technology sales surge, yet GAAP diluted EPS fell to $0.70 from $0.80 amid lower U.S. margins from glove pricing and promotions. The company recorded $23 million in restructuring costs, targeting over $100 million annual savings by year-end, while repurchasing $259 million in shares. Guidance holds steady for 2-4% sales growth and $4.80-$4.94 non-GAAP EPS. Restructuring risks could delay efficiencies.
8-K
CEO Bergman retires end-2025
Henry Schein announced CEO Stanley M. Bergman's retirement effective December 31, 2025, after 35 years steering the company from $225 million revenue in 1989 to nearly $13 billion in 2024, with a non-GAAP EPS CAGR of 12.4%. Bergman stays on as Chairman, while the Board launches a search for his successor amid the BOLD+1 strategy's momentum. Succession planning highlights strong divisional leaders. Smooth transition ahead.
8-K
Henry Schein, Inc. (Nasdaq: HSIC) announced amendments to its credit agreements. The term loan credit agreement, originally dated July 11, 2023, has been amended and restated effective June 6, 2025, extending the maturity to June 6, 2030. The revolving credit agreement, dated August 20, 2021, has been amended and restated effective June 6, 2025, maintaining the maturity date of July 11, 2028. These actions reflect the company's strategic financial management.
Henry Schein, Inc. has amended and restated its term loan credit agreement dated July 11, 2023, effective June 6, 2025, extending the maturity to June 6, 2030, and modified certain financial covenants and definitions. The company also amended and restated its revolving credit agreement dated August 20, 2021, effective June 6, 2025, with no changes to the maturity date of July 11, 2028. These amendments are part of the company's ongoing management of its debt facilities.
IPO
Website
Employees
Sector
Industry
CAH
Cardinal Health, Inc.
164.47+1.68
COR
Cencora, Inc.
333.17-2.47
EBOSF
EBOS GROUP
23.75+0.00
HCSG
Healthcare Services Group, Inc.
18.81-0.42
HLYK
HealthLynked Corp.
1.63+0.00
MCK
McKesson Corporation
807.63+3.04
MHUA
Meihua International Medical Te
0.23-0.03
OMI
Owens & Minor, Inc.
5.22-0.06
XRAY
DENTSPLY SIRONA Inc.
12.86-0.21
ZIMV
ZimVie Inc.
18.99+0.00